Accelerating precision medicine in metastatic prostate cancer

Joaquin Mateo, Rana McKay, Wassim Abida, Rahul Aggarwal, Joshi Alumkal, Ajjai Alva, Felix Feng, Xin Gao, Julie Graff, Maha Hussain, Fatima Karzai, Bruce Montgomery, William Oh, Vaibhav Patel, Dana Rathkopf, Matthew Rettig, Nikolaus Schultz, Matthew Smith, David Solit, Cora SternbergEliezer Van Allen, David VanderWeele, Jake Vinson, Howard R. Soule, Arul Chinnaiyan, Eric Small, Jonathan W. Simons, William Dahut, Andrea K. Miyahira, Himisha Beltran*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.

Original languageEnglish (US)
Pages (from-to)1041-1053
Number of pages13
JournalNature Cancer
Issue number11
StatePublished - Nov 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Accelerating precision medicine in metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this